831 related articles for article (PubMed ID: 17671140)
1. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
[TBL] [Abstract][Full Text] [Related]
3. Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells.
Kato Y; Yoshino I; Egusa C; Maeda T; Pili R; Tsuboi R
J Dermatol Sci; 2014 Aug; 75(2):140-7. PubMed ID: 24866536
[TBL] [Abstract][Full Text] [Related]
4. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
[TBL] [Abstract][Full Text] [Related]
5. Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma.
Huang P; Kaku H; Chen J; Kashiwakura Y; Saika T; Nasu Y; Urata Y; Fujiwara T; Watanabe M; Kumon H
Cancer Gene Ther; 2010 Jul; 17(7):484-91. PubMed ID: 20168351
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model.
Takeuchi T; Konno-Takahashi N; Kasuya Y; Ogushi T; Nishimatsu H; Kitamura T
BJU Int; 2004 Jul; 94(1):171-6. PubMed ID: 15217455
[TBL] [Abstract][Full Text] [Related]
9. Effect of interferon-alpha A/D in combination with the Japanese and Chinese traditional herbal medicine juzen-taiho-to on lung metastasis of murine renal cell carcinoma.
Muraishi Y; Mitani N; Yamaura T; Fuse H; Saiki I
Anticancer Res; 2000; 20(5A):2931-7. PubMed ID: 11062703
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration.
Hara I; Nagai H; Miyake H; Yamanaka K; Hara S; Micallef MJ; Kurimoto M; Gohji K; Arakawa S; Ichihashi M; Kamidono S
Cancer Gene Ther; 2000 Jan; 7(1):83-90. PubMed ID: 10678360
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor effects of AMT in the renal cell carcinoma model.
Caballero M; Scheele J; Zirrgiebel U; Esser N; Schächtele C; Soltau J; Rentschler J; Diergarten K; Drevs J
Oncol Rep; 2010 Jan; 23(1):205-10. PubMed ID: 19956883
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.
Dalgard CL; Van Quill KR; O'Brien JM
Clin Cancer Res; 2008 May; 14(10):3113-23. PubMed ID: 18483379
[TBL] [Abstract][Full Text] [Related]
13. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
16. [Antitumor activity of UFT against murine renal cell carcinoma: a study on the suppression tumor metastases].
Fujioka T; Hasegawa M; Ishikura K; Nomura K; Okamoto T; Tanji S; Koike H; Kubo T
Gan To Kagaku Ryoho; 1990 Oct; 17(10):2031-6. PubMed ID: 2221926
[TBL] [Abstract][Full Text] [Related]
17. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.
Qian DZ; Ren M; Wei Y; Wang X; van de Geijn F; Rasmussen C; Nakanishi O; Sacchi N; Pili R
Prostate; 2005 Jun; 64(1):20-8. PubMed ID: 15651062
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of synergistic antitumor effect of sorafenib and interferon-α on treatment of renal cell carcinoma.
Takeuchi A; Eto M; Tatsugami K; Yamada H; Oki T; Kiyoshima K; Yoshikai Y; Naito S
J Urol; 2010 Dec; 184(6):2549-56. PubMed ID: 21030044
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R
Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]